Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19"

NCT04475991 is registered in ClinicalTrials.gov with Hospital General de México Dr. Eduardo Liceaga as lead sponsor.

NCT NCT04475991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04475991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19"
Lead sponsor
Hospital General de México Dr. Eduardo Liceaga
Phase
Phase 2
Overall status
Terminated
Start date
July 13, 2021
Completion date
March 25, 2022
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19